Английская Википедия:Anteris Technologies

Материал из Онлайн справочника
Версия от 12:29, 1 февраля 2024; EducationBot (обсуждение | вклад) (Новая страница: «{{Английская Википедия/Панель перехода}} {{Short description|Australian biotechnology company}} {{Use Australian English|date=March 2023}} {{Use dmy dates|date=March 2023}} {{Infobox company | name = Anteris Technologies Limited | former_name = {{Unbulleted list|Allied Healthcare Group (2011–2013)|Admedus (2013–2020)}} | type = Public | traded_as = {{ASX|AVR}} | industry = Biotechnology | hq_location_c...»)
(разн.) ← Предыдущая версия | Текущая версия (разн.) | Следующая версия → (разн.)
Перейти к навигацииПерейти к поиску

Шаблон:Short description

Шаблон:Use Australian English Шаблон:Use dmy dates Шаблон:Infobox company

Anteris Technologies Limited is an Australian biotechnology company.

History

Anteris originates from the merger of Allied Medical and BioMD. Allied Medical was a company spun out of mining company Fortescue Metals Group in 2005 which focused on selling medical equipment such as catheters.[1] It entered the biotechnology space in July 2010 when it purchased a 38.6 per cent stake in Brisbane-based Coridon for A$3 million.[2] By February 2011, its stake increased to 55 per cent.[3] In February 2011, Allied Medical agreed to a reverse takeover deal with BioMD, a listed biotech company.[3] The takeover was completed in June 2011 resulting in the combined company, Allied Healthcare Group, listing on the Australian Securities Exchange (ASX).[4][5][6]

In September 2012, Allied raised $10.4 million to launch CardioCel across Europe.[7] In November 2013, Allied Healthcare changed its name to Admedus.[8] In December 2013, Admedus purchased a manufacturing site in Malaga to scale-up production of CardioCel and support the development and manufacture of additional regenerative tissue products.[7]

In October 2019, Admedus sold its CardioCel and VascuCel patch business to U.S.-based LeMaitre Vascular.[9] Under the agreement, Admedus received A$22.8 million upfront followed by deferred payments of $1 million each at 12 months and at 36 months. Additionally, the company could receive up to $11.4 million in earn-out payments.[10] Admedus retained the right to manufacture CardioCel and VascuCel products at its Malaga facility for LeMaitre over the following three years.[9] In May 2020, Admedus changed its name to Anteris Technologies.[11]

References

External links